OpenAI 收购 Orchestra Bio，拟打造加速药物研发的 AI 智能体
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI 收购了帮助药企团队协调药物研发的初创公司 Orchestra Bio，并将其并入生命科学平台 Rosalind。Orchestra 的智能体用于跟踪试验、在出现生产批次失败等问题时标记受影响的时间线，并给出后续选项。OpenAI 称在美国开发一款药物平均需要 10 到 15 年，交易金额未披露。
同一件事另外 1 家也报道了
- TechCrunch · AI··首发
- The Decoder··+11 小时 58 分·当前阅读
OpenAI 收购 Orchestra Bio，拟打造加速药物研发的 AI 智能体
新增信息：OpenAI 提到在美国开发一款药物平均需要 10 到 15 年。
按发布时间排列 · 事件后续出现时自动追加 · 由模型根据各家标题与摘要比对
OpenAI is making a bigger bet on pharmaceuticals. The company acquired Orchestra Bio, a startup that helps pharma teams coordinate drug development. Orchestra will be folded into Rosalind, OpenAI's AI platform for life sciences. GPT-Rosalind helps researchers analyze biological and chemical questions, while Rosalind Workbench connects those capabilities with scientific data and tools.
The combined effort aims to build AI agents that link scientific findings with clinical trials, decisions, and next steps to get new drugs to patients faster. Developing a drug in the US takes ten to 15 years on average. Beyond the scientific hurdles, siloed systems and the constant back-and-forth between internal teams and outside partners slow things down.
Orchestra's agents are designed to take work off teams' plates by tracking trials, flagging affected timelines when something goes wrong like a failed production batch, and surfacing options for what to do next. That could free scientists to focus on decisions and the actual research. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research. Financial terms of the deal weren't disclosed.
AI News Without the Hype – Curated by Humans
Subscribe to THE DECODER for ad-free reading, a weekly AI newsletter, our exclusive "AI Radar" frontier report six times a year, full archive access, and access to our comment section.
来源: The Decoder · the-decoder.com